ZD1839 (IRESSA™) in Combination With Docetaxel & Cisplatin in Subjects With Metastatic Head & Neck Cancer

NCT00242762 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Head and Neck Cancer

Interventions

DRUG: ZD1839 (IRESSA™)
DRUG: Docetaxel
DRUG: Cisplatin

Sponsor

AstraZeneca